CN112843092A - Application of immune cells in treating diseases and preparation method thereof - Google Patents
Application of immune cells in treating diseases and preparation method thereof Download PDFInfo
- Publication number
- CN112843092A CN112843092A CN202110071865.7A CN202110071865A CN112843092A CN 112843092 A CN112843092 A CN 112843092A CN 202110071865 A CN202110071865 A CN 202110071865A CN 112843092 A CN112843092 A CN 112843092A
- Authority
- CN
- China
- Prior art keywords
- antibody
- immune cells
- monoclonal antibody
- cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002865 immune cell Anatomy 0.000 title claims abstract description 27
- 201000010099 disease Diseases 0.000 title claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 210000004698 lymphocyte Anatomy 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 230000006698 induction Effects 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- 210000005087 mononuclear cell Anatomy 0.000 claims description 6
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 229920001917 Ficoll Polymers 0.000 claims description 4
- 102100037850 Interferon gamma Human genes 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000012091 fetal bovine serum Substances 0.000 claims description 4
- 239000012894 fetal calf serum Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 208000010531 varicella zoster infection Diseases 0.000 claims 2
- 208000004898 Herpes Labialis Diseases 0.000 claims 1
- 206010067152 Oral herpes Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 26
- 241000701085 Human alphaherpesvirus 3 Species 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 16
- 102100021696 Syncytin-1 Human genes 0.000 abstract description 9
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract description 7
- 238000009739 binding Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 3
- 238000010172 mouse model Methods 0.000 abstract description 2
- 208000007514 Herpes zoster Diseases 0.000 description 21
- 210000004405 cytokine-induced killer cell Anatomy 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 12
- 229960004150 aciclovir Drugs 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229940093257 valacyclovir Drugs 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 241001529453 unidentified herpesvirus Species 0.000 description 3
- 206010004542 Bezoar Diseases 0.000 description 2
- 241001678559 COVID-19 virus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 2
- 239000008923 Qingkailing Substances 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JBVSSSZFNTXJDX-YTLHQDLWSA-N Ala-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)N JBVSSSZFNTXJDX-YTLHQDLWSA-N 0.000 description 1
- NFDVJAKFMXHJEQ-HERUPUMHSA-N Ala-Asp-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N NFDVJAKFMXHJEQ-HERUPUMHSA-N 0.000 description 1
- KXEVYGKATAMXJJ-ACZMJKKPSA-N Ala-Glu-Asp Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O KXEVYGKATAMXJJ-ACZMJKKPSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 1
- ATABBWFGOHKROJ-GUBZILKMSA-N Arg-Pro-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O ATABBWFGOHKROJ-GUBZILKMSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- BSBNNPICFPXDNH-SRVKXCTJSA-N Asn-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)N)N BSBNNPICFPXDNH-SRVKXCTJSA-N 0.000 description 1
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 1
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 240000008537 Burchellia bubalina Species 0.000 description 1
- 235000004415 Burchellia bubalina Nutrition 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- WXKWQSDHEXKKNC-ZKWXMUAHSA-N Cys-Asp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CS)N WXKWQSDHEXKKNC-ZKWXMUAHSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 1
- ZEEPYMXTJWIMSN-GUBZILKMSA-N Gln-Lys-Ser Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@@H](N)CCC(N)=O ZEEPYMXTJWIMSN-GUBZILKMSA-N 0.000 description 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 1
- IVGJYOOGJLFKQE-AVGNSLFASA-N Glu-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N IVGJYOOGJLFKQE-AVGNSLFASA-N 0.000 description 1
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 1
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- QITBQGJOXQYMOA-ZETCQYMHSA-N Gly-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QITBQGJOXQYMOA-ZETCQYMHSA-N 0.000 description 1
- HAXARWKYFIIHKD-ZKWXMUAHSA-N Gly-Ile-Ser Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HAXARWKYFIIHKD-ZKWXMUAHSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 1
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- YGHSQRJSHKYUJY-SCZZXKLOSA-N Gly-Val-Pro Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN YGHSQRJSHKYUJY-SCZZXKLOSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- -1 IFN-r Proteins 0.000 description 1
- LPFBXFILACZHIB-LAEOZQHASA-N Ile-Gly-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)O)N LPFBXFILACZHIB-LAEOZQHASA-N 0.000 description 1
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 description 1
- WIDZHJTYKYBLSR-DCAQKATOSA-N Leu-Glu-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WIDZHJTYKYBLSR-DCAQKATOSA-N 0.000 description 1
- CPONGMJGVIAWEH-DCAQKATOSA-N Leu-Met-Ala Chemical compound CSCC[C@H](NC(=O)[C@@H](N)CC(C)C)C(=O)N[C@@H](C)C(O)=O CPONGMJGVIAWEH-DCAQKATOSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- LJBVRCDPWOJOEK-PPCPHDFISA-N Leu-Thr-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LJBVRCDPWOJOEK-PPCPHDFISA-N 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- GLJZDMZJHFXJQG-BZSNNMDCSA-N Phe-Ser-Phe Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O GLJZDMZJHFXJQG-BZSNNMDCSA-N 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 1
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000583907 Taraka Species 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 1
- RKDFEMGVMMYYNG-WDCWCFNPSA-N Thr-Gln-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O RKDFEMGVMMYYNG-WDCWCFNPSA-N 0.000 description 1
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 1
- SPVHQURZJCUDQC-VOAKCMCISA-N Thr-Lys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O SPVHQURZJCUDQC-VOAKCMCISA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- XZUBGOYOGDRYFC-XGEHTFHBSA-N Thr-Ser-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O XZUBGOYOGDRYFC-XGEHTFHBSA-N 0.000 description 1
- RPVDDQYNBOVWLR-HOCLYGCPSA-N Trp-Gly-Leu Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O RPVDDQYNBOVWLR-HOCLYGCPSA-N 0.000 description 1
- ILDJYIDXESUBOE-HSCHXYMDSA-N Trp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ILDJYIDXESUBOE-HSCHXYMDSA-N 0.000 description 1
- NESIQDDPEFTWAH-BPUTZDHNSA-N Trp-Met-Asp Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O NESIQDDPEFTWAH-BPUTZDHNSA-N 0.000 description 1
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- OLYXUGBVBGSZDN-ACRUOGEOSA-N Tyr-Leu-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 OLYXUGBVBGSZDN-ACRUOGEOSA-N 0.000 description 1
- SZEIFUXUTBBQFQ-STQMWFEESA-N Tyr-Pro-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SZEIFUXUTBBQFQ-STQMWFEESA-N 0.000 description 1
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940124397 anti-herpes virus drug Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 210000004889 cervical nerve Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HNGDOSBFYRVIEY-UHFFFAOYSA-N ethanesulfonic acid;hydrate Chemical compound O.CCS(O)(=O)=O HNGDOSBFYRVIEY-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 108010051307 glycyl-glycyl-proline Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000001937 intercostal nerve Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 239000009254 shuang-huang-lian Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000003901 trigeminal nerve Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to an application of immune cells in treating diseases and a preparation method thereof, wherein the immune cells comprise a monoclonal antibody specifically aiming at varicella-zoster virus envelope glycoprotein, the monoclonal antibody has better binding property and virus inhibiting effect, and meanwhile, the monoclonal antibody and the immune cells are found in a mouse model through experiments, so that the treatment effect on the virus infection of the skin of a mouse can be effectively improved, and the monoclonal antibody has better application value and application prospect.
Description
Technical Field
The invention relates to the field of biology, and in particular relates to application of immune cells in treating diseases and a preparation method thereof.
Background
Herpes Zoster (HZ) is a varicella-zoster virus (VZV) that remains dormant for a long time in the dorsal root ganglion of the spinal nerve or the cranial nerve sensory ganglion, and after reactivation and growth, migrates along nerve fibers to the skin to cause acute infectious skin inflammation, often manifested as herpes caused by the corresponding segments of the sensory nerve, with severe neuralgia. Generally, there are 4 areas of good hair: in the intercostal nerve, cervical nerve, trigeminal nerve and lumbosacral nerve innervating area, the affected part is usually initially provided with erythema, then becomes papule to soybean-sized papule which is distributed in clusters without fusion, finally becomes clustered blister, the blister wall is tensed and shines, the blister liquid is clear, the periphery is wound with areola, the skin among the clusters of blister is normal, and the skin lesion is mostly arranged in a belt shape along the peripheral nerve on one side. The course of the disease is usually 2-3 weeks, and the blisters dry, scab and fall off, leaving temporary reddish spots or pigmentation.
It was found that one of the important factors for maintaining the cellular immune function is the balance of Th1/Th2, while the Th1/Th2 cytokine levels in HZ patients are just out of balance, which is mainly expressed as: compared with normal human, the level of interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-alpha) representing Th1 type is obviously reduced, the corresponding cellular immune function is weakened, and the level of IL-4 representing Th2 type is obviously increased. The weakened immune function of Th1 cells means that the immune function of specific cells with inhibition effect on herpes virus in organisms is weakened, while interleukin-4 (IL-4) in HZ patients is increased, the function of Th2 cells is enhanced, and the inhibition effect on IL-2 and TNF-alpha biological activity is also enhanced; high levels of IL-4 immune status may result in a reduction in the body's ability to activate lymphocytes and NK cells, reducing their ability to lyse virus-infected cells. That is, after the balance of Th1/Th2 of cells in a VZV infected patient is disrupted, the body-specific immune function is reduced, and the VZV is more easily survived and proliferated in a large amount in the patient, thereby destroying more immune mechanisms of the body and triggering neuropathy of the affected part of the body.
The medicine for treating herpes zoster in acute stage comprises western medicines such as antiviral medicine and non-antiviral medicine, Chinese medicinal preparation and Chinese patent medicine. Common antiviral drugs such as famciclovir and penciclovir are nucleoside anti-herpes virus drugs and can be used for acute-stage treatment of herpes zoster. The antiviral drug acyclovir is also called acyclovir, is a synthesized purine nucleoside analogue, plays an antiviral role mainly by interfering virus deoxyribonucleic acid (DNA) synthesis, is a preferred drug for treating herpes zoster, has two common dosage forms of oral administration and external administration, but generally has low oral bioavailability and can achieve the treatment effect by large dose and multiple oral administrations. Valacyclovir is a prodrug of acyclovir, is good in absorption and fast in conversion, and has the bioavailability 3-4 times higher than that of acyclovir, but the results of the clinical curative effects of valacyclovir and acyclovir on treating herpes zoster compared with those of valacyclovir and acyclovir in the Yangtze river and the like show that the clinical total effective rate of valacyclovir on treating herpes zoster has no statistical significance with the difference of acyclovir. Interferons (IFNs) are broad-spectrum antiviral drugs, classified as alpha- (leukocyte) type, beta- (fibroblast) type, and gamma- (lymphocyte) type. IFN can inhibit the transcription, replication and release of viruses and can increase the activity of natural killer lymphotoxin. The results of combined application of IFN and valacyclovir to herpes zoster of Uylor and the like show that the effective rate of the combined drug group is 97.78 percent, the combined drug group is obviously higher than that of a valacyclovir group used alone, and the occurrence rates of pain relieving, blister stopping and crusting time, PHN and the like are lower than that of the valacyclovir group used alone.
The Chinese patent medicine for clinically treating herpes zoster mainly has the functions of cooling blood, removing toxicity, removing dampness-heat, promoting blood circulation, removing blood stasis, promoting qi circulation, relieving pain and the like. The clinical application of the chamomile to the treatment of herpes zoster by combining the compound isatis root granules, the salvia miltiorrhiza injection and the astragalus injection with the acyclovir eye drops shows that the Chinese patent medicine and the acyclovir eye drops can rapidly relieve pain and relieve blisters, are favorable for nerve recovery and reduce the generation of PHN. The gentian liver-fire-purging pill and the same-kernel bezoar heart-fire-clearing pill are taken together to treat the herpes zoster, and the total effective rate reaches 93.3 percent after 30 days of treatment. The Suwengui is used for treating the herpes zoster by combining the QINGKAILING injection with traditional Chinese medicine external washing, and the result shows that the components of the QINGKAILING injection, such as the bezoar, the buffalo horn, the baical skullcap root, the honeysuckle, the gardenia jasminoides ellis and the like, have the effects of clearing heat, purging pathogenic fire, clearing heat, detoxifying and the like, can improve the cure rate of the herpes zoster, shorten the cure time and control the incidence rate of sequelae. In addition, the Chinese patent medicines such as Shuanghuanglian, Chuanhuning and Xiyanping injection are reported to have better treatment effect on the herpes zoster.
In recent years, antibody drugs for the treatment of viruses have become extremely hot. However, monoclonal antibodies against herpes zoster virus have not been much studied. The research of Wuhan virus research of Chinese academy of sciences in 2018 makes an important progress in the research of screening neutralizing antibodies against herpes simplex virus, and the team successfully screens a new monoclonal antibody m27f, finds that the monoclonal antibody recognizes a new continuous epitope in envelope glycoprotein and has higher activity of neutralizing antibodies. But no further studies of antibodies related to herpes zoster virus were performed.
The CIK cells are a cell group generated by inducing and culturing peripheral blood mononuclear cells in vitro through various cytokines, are easy to culture and rapid to expand, are killer cells with high cytotoxicity and have obvious antiviral activity. CIK cell therapy is one of adoptive immunotherapy, which is an active immune cell with NK cell function obtained by culturing lymphocyte populations separated from peripheral blood, bone marrow or umbilical blood under the induction of various cytokines IL-2, IL-1, IFN-r, anti-CD 3 monoclonal antibodies and the like for a certain time, can identify cells infected by various viruses, inhibits and kills the replication of tumor cells and viruses by directly contacting with target cells and killing or secreting various antiviral cytokines such as IFN-r, TNF-a, IL-6 and the like, effectively regulates the immune function of an organism, and improves the anti-tumor and anti-virus capability of a patient organism. However, the number of immune cells adopted in the prior art for treating herpes viruses is not large, and further development is needed.
Disclosure of Invention
On one hand, the invention overcomes the defects of the prior art and provides a monoclonal antibody which adopts immune cells and is specifically directed at varicella-zoster virus envelope glycoprotein, and the monoclonal antibody has better binding property and virus inhibiting effect.
In one aspect of the present invention, a prepared CIK cell is provided, wherein the CIK cell is prepared by a method conventional in the art. The method for producing the obtained CIK cells can also be used in the method of example 1.
In another aspect, CIK cells are prepared as follows: adding normal peripheral blood into normal saline 1: 1, after dilution, slowly adding the blood mixture onto a Ficoll lymphocyte separation solution along the tube wall by using a suction tube, and centrifuging for 20min at 800g and 4 ℃; carefully sucking the second white cloudy mononuclear cell layer with a pipette into a centrifugal tube, adding normal saline, centrifuging at 4 deg.C for 10min for 3 times at 400g, and adjusting cell concentration to 1.0 × 106Per mL; inoculating the cells to a T175 culture bottle coated with a CD3 monoclonal antibody in advance, adding a BPMI-1640 culture medium containing 10% fetal bovine serum, adding 50 mu g/L of IL-2, 50 mu g/L of IFN-gamma and 25 mu g/L of IL-22, placing the mixture in a 5% CO2 cell culture box at 37 ℃ for induction culture, replacing the culture medium by half every day, and culturing for 10d to obtain the cells, namely the CIK cells.
In another aspect of the invention, a monoclonal antibody specific for varicella-zoster virus envelope glycoprotein is provided, wherein the monoclonal antibody has good binding property and virus inhibition effect. Specifically, the light chain variable region sequence of the monoclonal antibody is shown as SEQ ID NO: 1, the heavy chain variable region sequence of the monoclonal antibody is shown as SEQ ID NO: 2, respectively.
In another aspect of the invention, wherein the monoclonal antibody is an antibody fragment.
Preferably, wherein the antibody fragment is selected from the group consisting of an scFv fragment, an Fab fragment, an F (ab ') 2 fragment and an Fab' fragment.
Further, the monoclonal antibodies of the invention may be humanized.
Furthermore, the invention also provides a coding gene of the anti-varicella-zoster virus monoclonal antibody.
Furthermore, the expression vector of the encoding gene of the anti-varicella-zoster virus monoclonal antibody.
Further, the present invention provides the use of the antibody against varicella-zoster virus for the manufacture of a medicament against varicella-zoster virus.
In a further aspect of the present invention, there is provided a pharmaceutical composition prepared by combining CIK cells with antibodies against varicella-zoster virus.
The pharmaceutical composition further comprises a pharmaceutically acceptable carrier.
The dosage form of the medicine is tablets, capsules, granules, pills, injections, soft extracts, suspending agents, dispersing agents, syrups, suppositories, gels, aerosols or patches.
In a final aspect of the invention, there is provided the use of a CIK cell and a varicella-zoster virus antibody in the preparation of a medicament against varicella-zoster virus.
Advantageous effects
The monoclonal antibody specifically aiming at the varicella-zoster virus envelope glycoprotein is developed, has better binding property and virus inhibiting effect, and can effectively improve the treatment effect on the virus infection of the skin of a mouse through experimental discovery in a mouse model together with CIK cells, thereby having better application value and application prospect.
Drawings
FIG. 1 is a Western-blot result chart, in which lanes 1 to 6 show the results of the binding reactions of the monoclonal antibody with VZV-pOKA virus strain, BTV-8, CHUV, EHDV-1, and influenza B virus Malaysia2506/04, respectively.
FIG. 2 is a graph showing the results of ELISA detection of monoclonal antibodies
Detailed Description
The invention discloses application of monoclonal antibody and immune cell in preparing medicament for preventing and/or treating human herpesvirus infection, and the technical personnel can use the content to reference and properly improve process parameters to realize the purpose. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
EXAMPLE 1 preparation of CIK cells
Adding normal peripheral blood 100mL into normal saline 1: 1, diluting, slowly adding the blood mixture onto the Ficoll lymphocyte separation solution along the tube wall with a pipette, and centrifuging at 800g and 4 deg.C for 20 min. Carefully sucking the second white cloudy mononuclear cell layer with a pipette into a centrifugal tube, adding normal saline, centrifuging at 4 deg.C for 10min for 3 times at 400g, and adjusting cell concentration to 1.0 × 106and/mL. Inoculating to T175 culture bottle coated with CD3 monoclonal antibody in advance, adding BPMI-1640 medium containing 10% fetal bovine serum, adding 50 μ g/L IL-2, 50 μ g/L IFN-gamma and 25 μ g/L IL-22, and culturing at 37 deg.C in 5% CO2 cell culture box. The medium was replaced half way through the day. Respectively taking mononuclear cells before induction and induction culturing CIK cells to 10 days by 1 × 106The supernatant was centrifuged off, resuspended in 600. mu.L of PBS and counted. The results showed that the suspended mononuclear cells were uniformly distributedIn the culture flask, the edge is regularly rounded. Under the induction of cytokines, the cells grew into colonies, and the number of cells is shown in table 1.
TABLE 1 CIK cell proliferation in vitro
Number of |
0 | 2 | 4 | 6 | 8 | 10 |
Number of cells | 1.0×106 | 8.0×106 | 3.2×107 | 1.8×108 | 1.5×109 | 7.0×109 |
As can be seen from table 1, CIK cells induced by three factors were able to proliferate faster.
And adding 100 mu L of cell suspension which is proliferated for 10d and originally separated into each flow tube and respectively labeled with a fluorescent monoclonal antibody (CD3-FITC) + (IgG1-PE), (CD8-PE) + (IgG1-FITC), (CD56-PE) + (IgG1-FITC), (CD3-FITC) + (CD56-PE), (CD3-FITC) + (CD8-PE), (IgG1-FITC) + (IgG1-PE) as a negative control, centrifuging and washing by PBS after keeping away from light for 20min at room temperature, adding 200 mu LPBS into each tube, and resuspending on a machine for detection. The results of the phenotypic analysis of CIK cells were obtained as shown in table 2.
TABLE 2 phenotypic analysis of CIK cells (x. + -. s)
Group of | CD3+ | CD8+ | CD56+ | CD3+ +CD8+ | CD3+ +CD56+ |
PBMC cells | 67.01±3.17 | 43.52±4.53 | 21.86±2.87 | 32.11±0.97 | 9.01±1.27 |
CIK cell | 98.09±2.97 | 76.53±3.12 | 25.37±3.01 | 90.31±1.94 | 25.30±1.83* |
As can be seen from Table 2, the proportion of CIK major effector cells CD3+ + CD56+ double positive cells after 10 days of induction culture was greatly increased compared to the non-induced PBMC cells (P < 0.05).
EXAMPLE 2 preparation of monoclonal antibody targeting varicella-zoster Virus envelope glycoprotein
Immunization of varicella-zoster virus envelope glycoprotein high antigen epitope peptide
According to the sequence of the envelope glycoprotein of the varicella-zoster virus, a high antigen epitope peptide is obtained by searching a conservation interval through a hydrophobic index, a structural domain and a sequence alignment of a plurality of strains of B virus, and the sequence is vaatlghfatsvifttyfcgrgldetn. The polypeptide is synthesized by Shanghai's work. 2mg of the dried polypeptide powder was dissolved in 500. mu.l of 2- (N-morpholine) ethanesulfonic acid Monohydrate (MES) buffer, 2mg of BSA was dissolved in 200. mu.l MES buffer, and 10mg of EDC was dissolved in 1ml of ddH2O, mixing 500. mu.l of polypeptide solution with 200. mu.l of BSA solution, adding 100. mu.l of EDC solution, mixing well for 2h at room temperature, dialyzing with PBS, and storing at-20 ℃ for later use. Fusing the components
The polypeptide is mixed with equal volume of Freund's complete adjuvant, 6 BALB/c female mice (antigen amount 100 ug/mouse) with 7 weeks of age are immunized by multi-point injection on the neck and back, and then 2 nd and 3 rd immunization are carried out respectively on 14 th and 28 th days by the same method and dosage (Freund's complete adjuvant is replaced by Freund's incomplete adjuvant). On day 10 after 3 rd immunization, the mice with the highest antibody level were selected, and 1 booster immunization (100 ug/mouse antigen) was performed by intraperitoneal injection, and splenocytes were taken for cell fusion after 4 days.
Take 1X 108Each splenocyte is matched with (1-2) × 107Myeloma cells in several logarithmic growth phases are mixed at a ratio of 7: 1 in a 50mL centrifuge tube, cell fusion is carried out by using a PEG1500 fusion agent according to a conventional method, a positive hybridoma cell strain is screened by indirect ELISA by using immune polypeptide as a coating antigen, and subcloning is continuously carried out for 3 times by using a limiting dilution method until the hybridoma cell strain capable of stably secreting the antibody is obtained. Using antibody subclass identificationAnd (4) determining the kit, and identifying the monoclonal antibody subclasses according to the instruction.
After spleen lymphocytes of an immunized mouse are fused with SP2/0 cells, 2 hybridoma cell strains which have the best positive effect and stably secrete monoclonal antibodies of anti-varicella-zoster virus envelope glycoprotein high-antigen epitope peptides are finally obtained through 3 times of subcloning and screening. Both the hybridoma cells and their monoclonal antibodies were designated "HHV-5F 3" and "HHV-6D 6".
The obtained monoclonal hybridoma cells are subjected to expanded culture, injected into the abdominal cavity of an F1 mouse (the center of medical laboratory animals in Guangdong province), ascites is collected after the abdominal cavity of the mouse is swollen, and the monoclonal antibody is obtained by purifying through a Protein-A affinity chromatography column. And (3) identifying the monoclonal antibody secreted by the hybridoma cell strain by using an antibody subclass identification kit, and determining that the two monoclonal antibodies consist of an IgG1 heavy chain and a kappa light chain.
Example 3 specific identification of HHV-5F3 monoclonal antibody
Varicella-zoster virus VZV-pOKA virus strain was purchased from the Wuhan virus institute of Chinese academy of sciences; the VZV-pOKA virus strain and other different virus strains BTV-8, CHUV, EHDV-1 and influenza B virus Malaysia2506/04 are respectively infected with BHK cells cultured in a 6-well plate, and cell proteins are extracted about 72 hours when cytopathic effect is obvious. PAGE electrophoresis is carried out on samples with the same amount of protein, then the samples are electrically transferred to a PVDF membrane, 5% skimmed milk is sealed for 1h at room temperature, a primary antibody (HHV-5F3) is incubated overnight at 4 ℃, a secondary antibody is incubated for 1h at room temperature after membrane washing, and chemiluminescence self-development is carried out after membrane washing. The Western-blot results show that the monoclonal antibody HHV-5F3 can specifically recognize VZV-protein and does not react with other viral proteins (FIG. 1).
ELISA: coating was carried out at a protein amount of 200 ng/well (3 wells per sample), and indirect ELISA was carried out according to a conventional method using HHV-5F3 monoclonal antibody as a primary antibody. The specificity of the antibody was also confirmed by the ELISA results of the detection of the monoclonal antibody HHV-5F3, the OD of which reached 0.34 (FIG. 2).
Example 4HHV-5F3 monoclonal antibody affinity and variable region identification
The experiment uses a Fortebio Octet molecular interaction instrument to detect the affinity constant of the single HHV-5F3 monoclonal antibody and the immune polypeptide.
The experimental method for detecting the affinity constant of the HHV-5F3 monoclonal antibody and the immune polypeptide by the Fortebio Octet molecular interaction instrument is as follows: the sample dilution buffer was PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4. mu.g/mL of the polypeptide was immobilized on the HIS1K sensor for 40s, the sensor was equilibrated in buffer for 55s, the polypeptide immobilized on the sensor was bound to the antibody at a concentration of 0.1-50nM for 100s, and the antibody was dissociated in buffer for 100 s. The sensor was regenerated using 10mM glycine, pH1.5, for a period of 5s, and repeated 4 times. The detection temperature was 30 ℃ and the frequency was 0.3 Hz. Data were expressed as 1: 1, carrying out model fitting analysis to obtain an affinity constant.
The result shows that the HHV-5F3 monoclonal antibody can be combined with the polypeptide, has the affinity constant of 6.83E-09M, and has better affinity effect.
Total RNA was extracted from the cultured HHV-5F3 monoclonal cell line using Trizol reagent. The total RNA was converted to cDNA using the reverse transcription cDNA kit from Taraka. The cDNA was further supplemented with polyG at the 3' end. The gene amplification of the antibody variable region was performed using the tailed cDNA as a template. The variable region sequences of the light chain and the variable region sequences of the heavy chain of the monoclonal antibody were obtained as follows:
light chain variable region (SEQ ID NO: 1)
Heavy chain variable region (SEQ ID NO: 2):
example 5 experiment of suppression of viruses by HHV-5F3 monoclonal antibody
Vero cells were cultured in DMEM medium containing 2% fetal bovine serum at 5X 104Inoculating 96-well culture plate at concentration of 100 μ L per well, standing at 37 deg.C and 5% CO2The cell monolayer was formed overnight in the incubator. After discarding the supernatant, the mixture was washed with PBSWashing the cells for 1 time to remove residual fetal calf serum, adding DMEM medium without fetal calf serum to dilute to 100TCID50VZV-pOKA virus (100. mu.L/well) was incubated at 35 ℃ for 2 hours, and then the virus solution was discarded. Preparing HHV-5F3 monoclonal antibody and positive control drug acyclovir into DMEM culture medium containing 2% fetal calf serum at different concentrations, adding into single-layer Vero cell, setting 3 multiple holes, and culturing at 37 deg.C and 5% CO in Vero cell2Culturing in an incubator for 48h, and observing cytopathic phenomenon every day. After 48h, the supernatant was discarded, 100. mu.L of 10% formaldehyde was added for fixation for 1h, 0.1% (w/v) crystal violet was stained for 15min, and the absorbance was measured by an microplate reader at 570 nm. The rate of virus inhibition was calculated, and EC50 (half effective concentration) of the HHV-5F3 monoclonal antibody against the virus was calculated. The test results are shown in table 3:
TABLE 3 antiviral Activity of HHV-5F3 mAb on VZV-pOKA
Medicine | EC50 |
HHV-5F3 monoclonal antibody | 0.83μM |
Acyclovir | 1.26μM |
Table 1 the results show that: the HHV-5F3 monoclonal antibody has obvious inhibition effect on cytopathic effect caused by human herpesvirus VZV-pOKA in vitro, has the EC50 of 0.83 mu M, and has the in vitro pharmacodynamic basis of being applied to treatment of herpesvirus infection.
Example 6 mouse experiment of virus inhibition by HHV-5F3 monoclonal antibody
Selecting 30 SPF grade 8 week old male C57 mice with weight of 18-22g, prepared from Shanghai university of medicineA central supply. After the sodium pentobarbital is anesthetized, the backs of the guinea pigs are unhaired, cleaned and disinfected according to a conventional method, and the unhaired parts of the backs of the mice are divided into a plurality of skin areas by a marking pen. Central intradermal injection 10 at each dermatome7PFU/mLVZV-pOKA virus strain virus, 0.1mL per injection. During anaesthesia, animals were kept in an incubator at 30 ℃ for 2 h. Respectively relating to a positive control group, an antibody + immune cell group, an immune cell group and a blank control group, wherein the positive control group is an acyclovir group; the antibody group was the monoclonal antibody group of the present invention, the antibody + immune cell group was the monoclonal antibody of the present invention + CIK cells prepared in example 1, the immune cell group was the CIK cells prepared in example 1, and the blank control group was smeared with PBS solution. Applying 30 μ L of the medicinal liquid each time, and continuously administering for 5 days after applying the medicinal liquid 2 times daily until the medicinal liquid is dried. The cure conditions of the pathological changes of the mice are observed day by day. The results are shown in Table 4.
TABLE 4 therapeutic Effect of topical administration on herpes Virus infection of the skin of mice
Administration group | Dosage form | Healing days (Tian) |
Positive control group | 10mg/kg/d | 10.56±1.38 |
Antibody group | 10mg/kg/d | 8.65±1.12 |
Antibody + immune cell group | 10mg/kg/d+5×109Per kg/d | 6.04±1.40 |
|
5×109Per kg/d | 12.68±1.34 |
Blank control group | -(PBS) | 19.32±1.02 |
The results in table 4 show that, after the skin of the mouse is inoculated with the infectious virus, the cure days of the groups coated with the antibody and the combination of the antibody and the immune cells are both significantly reduced compared with the positive control, particularly the combination of the antibody and the immune cells can be cured within 6.04 days of the minimum pharmaceutical preparation. The antibody and the combination of the antibody and the immune cells have treatment effect on the virus infection of the skin of the mouse, can shorten the recovery time, and have better effect. And by detecting the visceral organs of the mice, no substantive lesion exists, which shows that the safety of the medicine can be guaranteed.
While the invention has been described and illustrated in detail as being sufficient to enable those skilled in the art to make and use it, various alternatives, modifications, and improvements should be apparent without departing from the spirit and scope of the invention. The examples provided herein represent preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Modifications thereof and other uses will occur to those skilled in the art. Such modifications are encompassed within the spirit of the invention and are defined by the scope of the claims.
Sequence listing
<110> Beijing Song Biotechnology Ltd
Application of <120> immune cell in treating diseases and preparation method thereof
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 108
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Asp Ile Val Ile Thr Gln Ser Pro Ala Leu Met Ala Ala Ser Pro Gly
1 5 10 15
Glu Lys Val Thr Ile Thr Cys Asp Val Ser Ser Ser Ile Gly Glu Lys
20 25 30
Tyr Leu Tyr Trp Tyr Gln Gln Lys Ser Gly Ile Ser Pro Lys Pro Trp
35 40 45
Ile Tyr Ser Thr Ser Asn Leu Glu Trp Gly Val Pro Ala Arg Phe Ser
50 55 60
Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Thr Ser Met Glu
65 70 75 80
Ala Glu Asp Ala Ala Thr Tyr Tyr Cys Ala Asp Trp Ser Gly Gly Pro
85 90 95
Phe Ser Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys
100 105
<210> 2
<211> 116
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Glu Val Gln Leu Glu Glu Ser Gly Thr Glu Leu Ala Arg Pro Ser Ala
1 5 10 15
Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Ser Ser Met
20 25 30
Trp Met Asp Trp Ile Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Ser Ile Tyr Pro Gly Ser Thr Ala Thr Arg Tyr Thr Gln Leu Ser
50 55 60
Gly Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Arg
65 70 75 80
Met Gln Leu Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Gly Ala Asn Phe Cys Phe Ser Ser Trp Gly Leu Gly Thr Thr Leu
100 105 110
Ala Val Ser Ser
115
Claims (8)
- The application of NIK immune cells in preparing medicaments for preventing and/or treating varicella-zoster virus infection of human beings; the NIK immune cells are prepared by the following method: adding normal peripheral blood into normal saline 1: 1, after dilution, slowly adding the blood mixture onto a Ficoll lymphocyte separation solution along the tube wall by using a suction tube, and centrifuging for 20min at 800g and 4 ℃; carefully sucking the second white cloudy mononuclear cell layer with a pipette into a centrifugal tube, adding normal saline, centrifuging at 4 deg.C for 10min for 3 times at 400g, and adjusting cell concentration to 1.0 × 106Per mL; inoculating to T175 culture bottle coated with CD3 monoclonal antibody in advance, adding BPMI-1640 culture medium containing 10% fetal calf serum, adding 50 μ g/L IL-2, 50 μ g/L IFN-gamma and 25 μ g/L IL-22, culturing at 37 deg.C in 5% CO2 cell culture box, and replacing half the culture every other dayCulturing the cells for 10 days to obtain the NIK immune cells.
- 2. The use according to claim 1, wherein the disease caused by infection is herpes labialis, pharyngitis, keratitis or sporadic encephalitis.
- The application of NIK immune cells and HHV-5F3 monoclonal antibodies in preparing pharmaceutical compositions for treating varicella-zoster virus infection of human beings; wherein the light chain variable region sequence of the antibody is shown in SEQ ID NO: 1, the heavy chain variable region sequence of the antibody is shown as SEQ ID NO: 2 is shown in the specification; the NIK immune cells are prepared by the following method: adding normal peripheral blood into normal saline 1: 1, after dilution, slowly adding the blood mixture onto a Ficoll lymphocyte separation solution along the tube wall by using a suction tube, and centrifuging for 20min at 800g and 4 ℃; carefully sucking the second white cloudy mononuclear cell layer with a pipette into a centrifugal tube, adding normal saline, centrifuging at 4 deg.C for 10min for 3 times at 400g, and adjusting cell concentration to 1.0 × 106Per mL; inoculating the cells in a T175 culture bottle coated with a CD3 monoclonal antibody in advance, adding a BPMI-1640 culture medium containing 10% fetal bovine serum, adding 50 mu g/L of IL-2, 50 mu g/L of IFN-gamma and 25 mu g/LIL-22, placing the mixture in a 5% CO2 cell culture box at 37 ℃ for induction culture, replacing the culture medium by half every day, and culturing for 10d to obtain the NIK immune cells.
- 4. The use according to any one of claims 1 to 3, wherein the medicament further comprises a pharmaceutically acceptable carrier.
- 5. The use of claim 4, wherein the pharmaceutical formulation is any one of clinically acceptable oral administration, injection administration or external administration.
- 6. The use according to claim 5, wherein the medicament is in the form of tablets, capsules, granules, pills, injections, creams, suspensions, dispersions, syrups, suppositories, gels, aerosols or patches.
- 7. The use according to any one of claims 1 to 3, wherein the active dose of said antibody is 10mg/kg body weight/d of the human body and the dose of said immune cells is 5 x 109One/kg body weight/d.
- The HHV-5F3 monoclonal antibody, characterized in that the light chain variable region sequence of said antibody is as set forth in SEQ ID NO: 1, the heavy chain variable region sequence of the antibody is shown as SEQ ID NO: 2, respectively.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110071865.7A CN112843092B (en) | 2021-01-20 | 2021-01-20 | Application of immune cell in treating diseases and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110071865.7A CN112843092B (en) | 2021-01-20 | 2021-01-20 | Application of immune cell in treating diseases and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112843092A true CN112843092A (en) | 2021-05-28 |
CN112843092B CN112843092B (en) | 2022-05-10 |
Family
ID=76007481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110071865.7A Active CN112843092B (en) | 2021-01-20 | 2021-01-20 | Application of immune cell in treating diseases and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112843092B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114790444A (en) * | 2022-05-09 | 2022-07-26 | 浙江大学医学院附属第一医院 | Immune cell subpopulations and products related thereto and method for assessing pain intensity in patients with herpes zoster |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641298A (en) * | 2012-05-15 | 2012-08-22 | 祁岩超 | Effector cell combination for preventing and treating tumors and preparation method thereof |
CN107789366A (en) * | 2016-09-05 | 2018-03-13 | 拜西欧斯(北京)生物技术有限公司 | Cell antibody compound and preparation method thereof |
US20180296509A1 (en) * | 2015-10-05 | 2018-10-18 | Quimica Luar Srl | Bactericidal and virucidal pharmaceutical composition |
CN108753724A (en) * | 2018-05-07 | 2018-11-06 | 广州沙艾生物科技有限公司 | A kind of immunocyte cultural method and its application |
-
2021
- 2021-01-20 CN CN202110071865.7A patent/CN112843092B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641298A (en) * | 2012-05-15 | 2012-08-22 | 祁岩超 | Effector cell combination for preventing and treating tumors and preparation method thereof |
US20180296509A1 (en) * | 2015-10-05 | 2018-10-18 | Quimica Luar Srl | Bactericidal and virucidal pharmaceutical composition |
CN107789366A (en) * | 2016-09-05 | 2018-03-13 | 拜西欧斯(北京)生物技术有限公司 | Cell antibody compound and preparation method thereof |
CN108753724A (en) * | 2018-05-07 | 2018-11-06 | 广州沙艾生物科技有限公司 | A kind of immunocyte cultural method and its application |
Non-Patent Citations (2)
Title |
---|
MARIUS BIRLEA等: "Human anti-varicella-zoster virus (VZV) recombinant monoclonal antibody produced after Zostavax immunization recognizes the gH/gL complex and neutralizes VZV infection", 《CASE REPORTS》 * |
RZO35182.1: "ABC transporter substrate-binding protein [Rhodobacteraceae bacterium]", 《GENBANK》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114790444A (en) * | 2022-05-09 | 2022-07-26 | 浙江大学医学院附属第一医院 | Immune cell subpopulations and products related thereto and method for assessing pain intensity in patients with herpes zoster |
Also Published As
Publication number | Publication date |
---|---|
CN112843092B (en) | 2022-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE68836B1 (en) | Use of interleukin-10 in adoptive immunotherapy of cancer | |
JP5209462B2 (en) | How to use consensus interferon | |
CN113563475B (en) | Bispecific antibody for resisting novel coronavirus and application thereof | |
CN111690050B (en) | TCR recognizing EBV-LMP2 antigen and corresponding nucleic acid molecule, vector, cell and drug | |
CN106554416B (en) | A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the protein (STING) agonist in antitumor | |
WO1992012725A1 (en) | Treatment of neoplastic disease with interleukin-10 | |
WO2023040835A1 (en) | Alpaca-derived nanobody and application thereof | |
CN112843092B (en) | Application of immune cell in treating diseases and preparation method thereof | |
CN113876938A (en) | Construction and application of fusion protein vaccine platform | |
JP6721419B2 (en) | Ezrin-derived peptide and pharmaceutical composition thereof | |
US20080019972A1 (en) | Method for Amplifying Therapeutic Vaccine Activity | |
CN112386688B (en) | A pharmaceutical composition containing immunocyte for treating virus | |
CN102633867A (en) | Antigenically-changed enterotoxin C2 mutant, coding gene thereof, preparation thereof and application thereof | |
CN111450248B (en) | Antibody medicine for preventing and treating PRRSV infection | |
CN109535231B (en) | CTL (cytotoxic T lymphocyte) specific recognition epitope of human T cell virus antigen protein Tax and application thereof | |
CN112175092A (en) | Dual-target chimeric antigen receptor simultaneously targeting LMP1 and GP350 and application thereof | |
CN114805596A (en) | Chimeric antigen receptor taking glypican 3 as target spot and application thereof | |
CN111499766A (en) | Immune effector cell aiming at chronic lymphocytic leukemia, preparation method and application thereof | |
CN112399858A (en) | Medical use | |
JPH1087506A (en) | Composition containing gamma-interferon for systematically treating various human diseases in low dose | |
US20080069800A1 (en) | System for High Production of Natural and Personalized Interferons | |
CN110876759A (en) | Application of M gene mutated vesicular stomatitis virus in antitumor drugs | |
CN1225016A (en) | Interleukin-8 as an antiviral and antitumor agent | |
Palladino et al. | Characterization of interleukin 2-dependent cytotoxic T-cell clones: IV. Production of α, β and γ interferons and interleukin 2 by Lyt-2+ T cells | |
WO2023198155A1 (en) | Antibody for treating skin and mucosal inflammation and formulation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220420 Address after: 830002 Room 201, unit 1, block a, No. 15 Bazhou Road, shayibak District, Urumqi, Xinjiang Uygur Autonomous Region Applicant after: Zhu Youjian Applicant after: Xinjiang Xinnuo ark Health Management Co., Ltd Address before: Room 1037, unit 1, 10 / F, building 18, No. A7, Tongji Middle Road, Daxing District, Beijing Applicant before: Beijing Xinsong Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |